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Highly Purified Mycobacterial Phosphatidylinositol Mannosides Drive
Cell-Mediated Responses and Activate NKT Cells in Cattle
Chris Pirson,a Regina Engel,b Gareth J. Jones,a Thomas Holder,a Otto Holst,b H. Martin Vordermeiera
TB Research Group, Animal Health and Veterinary Laboratories Agency, New Haw, Addlestone, Surrey, United Kingdoma; Division of Structural Biochemistry, Research
Centre Borstel, Leibniz-Centre for Medicine and Biosciences, Borstel, Germanyb
Mycobacterial lipids play an important role in the modulation of the immune response upon contact with the host. Using novel
methods, we have isolated highly purified phosphatidylinositol mannoside (PIM)molecules (phosphatidylinositol dimannoside
[PIM2], acylphosphatidylinositol dimannoside [AcPIM2], diacyl-phosphatidylinositol dimannoside [Ac2PIM2], acylphosphati-
dylinositol hexamannoside [AcPIM6], and diacylphosphatidylinositol hexamannoside [Ac2PIM6]) from virulentMycobacterium
tuberculosis to assess their potential to stimulate peripheral blood mononuclear cell (PBMC) responses inMycobacterium bovis-
infected cattle. Of these molecules, one (AcPIM6) induced significant levels of gamma interferon (IFN-) in bovine PBMCs.
Three PIMmolecules (AcPIM6, Ac2PIM2, and Ac2PIM6) were shown to drive significant proliferation in bovine PBMCs. AcPIM6
was subsequently used to phenotype the proliferating cells by flow cytometry. This analysis demonstrated that AcPIM6 was pre-
dominantly recognized by CD3 CD335NKT cells. In conclusion, we have identified PIM lipid molecules that interact with
bovine lymphocyte populations, and these lipids may be useful as future subunit vaccines or diagnostic reagents. Further, these
data demonstrate, for the first time, lipid-specific NKT activation in cattle.
Members of the mycobacterial genus are renowned for theirwaxy, lipid-rich outer envelope. Under physiological condi-
tions, this outer layer is likely to be the first point of contact be-
tween the bacterial cell and the host’s immune system, and the
outcome of this interaction is pivotal in the establishment of in-
fection. One of the most important groups of membrane bound
lipids consists of the phosphatidylinositol mannosides (PIMs).
Interest in PIMs was stimulated since it was shown that phospha-
tidylinositol dimannoside (PIM2) forms the phosphoglycolipid
anchor which tethers a large array of glycolipids and lipoglycans,
including lipomannan (LM) and lipoarabinomannan (LAM), to
the cellularmembrane (1). PIMs have been shown to interact with
a variety of immune components and mediate significant effects
on the host. Ever since the realization that NKT cells could re-
spond to lipid antigens (2–4) and the subsequent discovery of the
CD1d-restricted lipid antigen -galactosylceramide (-GalCer)
(5, 6),much research effort has been concentrated on understand-
ing lipid antigens. Although work was initially focused on invari-
ant NKT cells, it has since been shown that great diversity exists in
the lipid-responsive T cell receptor (TCR) repertoire (7–9) and
that these diverse NKT cells contribute to the Th1/Th2 balance (7,
10). It has been shown that CD1d-restricted NKT cells are capable
of recognizing a variety of lipid antigens, including phospholipids
(11). More recently, a CD1b-restricted subset of T cells has been
found (12). Similarly to CD1d-restricted invariant NKT (iNKT)
cells, the CD1b-restricted variant cells require CD1B for their de-
velopment and produce proinflammatory cytokines in response
to CD1b-expressing dendritic cells (DCs) (12). It is clear that
NKT-like cells have a significant role to play in lipid-mediated
responses, and the hunt for their antigens has continued (13–15).
Given the ability of lipid molecules to generate responses in
peripheral bloodmononuclear cells (PBMC), we decided to assess
the ability of individual, highly purified natural PIMs to activate
bovine lymphocytes. In this study, we developed a novel extrac-
tion method which allowed us to extract and highly purify a vari-
ety of PIM molecules from virulent Mycobacterium tuberculosis
H37Rv. The ability of these molecules to induce lymphocyte re-
sponses inMycobacterium bovis-infected cattle was investigated by
measuring lymphocyte proliferation and gamma interferon
(IFN-) production. Furthermore, flow cytometry techniques
were utilized to characterize responding cell populations.
MATERIALS AND METHODS
Extraction of PIMs. Using the novel methodology outlined below,
highly pure phosphatidylinositol dimannoside (PIM2), acylphosphati-
dylinositol dimannoside (AcPIM2), diacyl-phosphatidylinositol diman-
noside (Ac2PIM2), acylphosphatidylinositol hexamannoside (AcPIM6),
and diacylphosphatidylinositol hexamannoside (Ac2PIM6) were success-
fully isolated. Individual PIM molecules were analyzed by electrospray
ionization mass spectrometry (ESI-MS) to confirm identity and purity as
shown in Fig. 1. Up to 1 g of dry bacterial mass of Mycobacterium tuber-
culosisH37Rvwas suspended in 20 to 30ml ofH2O and ruptured utilizing
a French press at a minimum of 20,000 kPa. This procedure was per-
formed five times, and the combined sample was lyophilized.
Up to 0.5 g of this lyophilized material was extracted three times ac-
cording to the method of Bligh and Dyer (16). The dry mass was sus-
pended in 4 ml of H2O and washed twice in an additional 2 ml of H2O
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before being transferred into a 100-ml Erlenmeyer flask. To this sample
was added 30 ml of CHCl3·CH3OH (1:2, vol/vol), and the sample was
sonicated (Branson Sonifier 250; output 2, 40%duty cycle, 20min). Then,
10 ml of CHCl3 was added, and the sample was sonicated for a further 5
min. Subsequently, an additional 10ml ofH2Owas added, and the sample
was sonicated for a final 5 min. The sample was decanted evenly into
between two and four 50-ml Nalgene Teflon tubes and centrifuged for 30
min at 10,000 g to generate three phases (a water phase, a CHCl3 phase,
and an interphase). The water phases (containing LAM and LM) were
removed, combined, and lyophilized, while the CHCl3 phases were trans-
ferred into a single 100-ml pear-shaped flask. The total yield of material
after three extractions was about 11% of the bacterial dry mass.
Since the remaining interphases contained a lot of AcPIM6, they were
suspended in 8 ml of H2O and combined into 30-ml Kimble high-speed
glass tubes before being lyophilized. These phases were then extracted
overnight with 30 ml of CHCl3·MeOH (1:2, vol/vol) using a shaker. The
sample was then centrifuged for 30 min at 10,000  g, and the
CHCl3·MeOH phase was removed. This phase was dried under an N2 gas
stream before being resuspended in equal parts of CHCl3·MeOH, filtered
through a 0.2-m-pore-size polytetrafluoroethylene (PTFE) filter, and
dried under N2. This extraction was repeated two times until no PIMs
could be identified (total yield of about 2% of the bacterial drymass). The
obtained PIMs were further purified with silica gel 60 chromatography
(see below), as were the CHCl3 phases of the Bligh and Dyer extraction.
Purification of PIMs. All samples were separated on a column (7 by 1
cm) of silica gel 60 (0.04 to 0.063 mm) which was successively eluted with
(i) 80 ml of CHCl3·MeOH (8:2, vol/vol), (ii) 60 ml of CHCl3·MeOH (1:1,
vol/vol), and finally (iii) 40 ml of CHCl3·MeOH·H2O (10:10:3, vol/vol/
vol). Coextracted cardiolipin and other lipids eluted in the first mobile
phase, most PIMs eluted in the second, and the rest of the PIMs eluted in
the third. Fractions ii and iii were dried under N2, resuspended in 10ml of
CHCl3·MeOH (8:2, vol/vol), and passed through a 0.2-m-pore-size
PTFE filter before being analyzed by high-performance thin-layer chro-
matography (HPTLC). HPTLC was performed using glass-backed 10- by
10-cm silica gel 60 plates (Merck KGAA, Darmstadt, Germany) run in
CHCl3·MeOH·H2O (10:8:2, vol/vol/vol) and stained with Hanessian’s
stain (0.5 g of ceric sulfate and 25 g of ammoniummolybdate in 470ml of
water supplemented with 30 ml of sulfuric acid with stirring) and visual-
ized at 150°C.
Fractions ii and iii from both of the CHCl3 phases of the Bligh and
Dyer extraction and the PIMs extracted from the interphase were then
further separated by high-performance liquid chromatography (HPLC)
using 5-mKromasil 100C18 columns (250 by 20mm) elutedwith eluent
A (CHCl3·MeOH·H2O [240:1,140:620, vol/vol/vol] containing 10 mM
NH4CH3CO2) and eluent B (CHCl3·MeOH [1,400:600, vol/vol] contain-
ing 50 mM NH4CH3CO2). The initial eluent B gradient was 15% for 60
min, followed by 20% for 140 min, 40% for 80 min, and finally 100% for
60min at 4mlmin1. Sampleswere detected by a light-scattering detector
(Sedex; nitrogen pressure, 2  105 Pa; temperature, 50°C; split, 1:70).
Samples were applied in 200 l of CHCl3·MeOH (8:2, vol/vol). For ana-
lytical runs, 10 g of sample was injected while 10 mg was injected for
preparative separations.
Since PIM2 and AcPIM6 coeluted on the C18 column, they were sepa-
rated byHPLC on 5-mProntosil 200-5-C30 reverse-phase columns (250
by 4.6 mm) using the same elution reagents. The initial eluent B gradient
was 5% for 5min, followed by 10% for 15min, 15% for 50min, and finally
100% for 10 min at 0.8 ml min1. Samples were injected as a mixture of
0.6mg in 80l of CHCl3·CH3OH·H2O (10:10:3, vol/vol/vol) and detected
by the light-scattering detector described above.
FIG 1 Mass spectrometric proof of purity of isolated PIMs. Identified molecular masses of PIM2 (calculated molecular mass, 1176.6784 u) (A), AcPIM2
(calculated molecular mass, 1442.9394 u) (B), Ac2PIM2 (calculated molecular mass, 1653.1378 u) (C), AcPIM6 (calculated molecular mass, 20147.0881 u) (D),
and Ac2PIM6 (calculated molecular mass, 2301.3491 u) (E). Letters in parentheses identify the peaks.
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Cattle.Blood samples were obtained from 10 naturally infected, single
intradermal comparative cervical tuberculin test-positive reactors (be-
tween 6 and 36 months of age). Animals were sourced from herds with
confirmed bovine tuberculosis breakdowns in Devon, Herefordshire, or
Worcestershire and were housed at the Animal Health and Veterinary
Laboratories Agency (AHVLA) at the time of blood sampling. Infection
was confirmed by necropsy andM. bovis culture in all animals. All proce-
dures involving animals were carried out under a project license granted
by the Home Office of Great Britain under the Animals (Scientific Proce-
dures) Act 1986. This project was approved by the local VLA Animal
Ethics Committee prior to submission to the Home Office.
Isolation of bovine PBMC from whole blood. Whole blood was
mixed in equal parts with sterile Hanks balanced salt solution (HBSS)
containing 10 U ml1 heparin. This mixture was overlaid onto His-
topaque 1077 (Sigma-Aldrich) and centrifuged at 800 g for 40min. The
PBMC interface was removed using a pastette and washed twice in HBSS
containing heparin. Live cells were identified via trypan blue exclusion
and enumerated using a hemocytometer.
Preparation of lipid antigen suspensions. Briefly, lipids were sus-
pended in an aqueous phase for use in cell culture experiments after re-
moval of CHCl3·CH3OH by evaporation using an N2 gas stream. Cell
culture medium was added to the dried lipid, and the mixture was sub-
jected to two cycles of heating at 80°C and then sonication for 5 min.
Lipids were used to stimulate cells in vitro at 20 g ml1 in all assays.
Lymphocyte proliferation assay. Bovine PBMC were prepared from
all 10 animals as described above and were cultured in complete cell cul-
ture medium (RPMI 1640 medium containing 25 mMHEPES, 10% fetal
calf serum [FCS], 1% nonessential amino acids [NEAA], 5  105 mM
2-mercaptoethanol, 100Uml1 penicillin, and 100gml1 streptomy-
cin [Gibco Life Technologies, Paisley, United Kingdom]) at 37°C in 5%
CO2 for 5 days in the presence of antigen at 2 10
5 cells well1. After 5
days, cells were pulsed with 1 Ci well1 of [3H]thymidine overnight,
before being harvested using a Harvester 96 Mach III (TomTec, Inc.,
Hamden, CT, USA). Lymphocyte proliferation was assessed by the in-
creased cellular incorporation of [3H]thymidine (cpm), which was mea-
sured using a MicroBeta2 2450 plate counter (PerkinElmer, Waltham,
MA, USA). Responses to individual PIMs were considered positive if the
cpm exceeded the mean plus 2 times standard deviation of cpm for non-
antigen-stimulated cultures from all 10 animals.
Measurement of IFN- by Bovigam ELISA. Levels of IFN- in 5-day
supernatants from the proliferation assay were determined using a Bo-
vigam enzyme-linked immunosorbent assay (ELISA) kit (Prionics AG,
Switzerland). Responses to individual PIMs were considered positive if
the optical density at 450 nm (OD450) exceeded the mean plus 2 times the
standard deviation of the OD450 for non-antigen-stimulated cultures
from all 10 animals.
Measurement of proliferation and phenotyping by flow cytometry.
Bovine PBMCwere isolated as described above and labeledwithCellTrace
violet (Invitrogen Molecular Probes, Paisley, United Kingdom) in accor-
dance with the manufacturer’s instructions. Briefly, PBMC were sus-
pended at 1  107 cells ml1 in prewarmed phosphate-buffered saline
(PBS), and 5 mM CellTrace violet was added to a final working concen-
tration of 1M. Cells were incubated at 37°C for 20 min before unbound
dye was quenched with five times the labeling volume of complete cell
culture medium at 37°C for 5 min. Finally, cells were pelleted and washed
in prewarmed complete cell culture medium, plated at 2  105 cells
well1, and incubated at 37°C in 5% CO2 for 5 days in the presence of
antigen.
Cultured cells were harvested and resuspended in flow cytometry buf-
fer (PBS containing 2%FCS and 0.05%NaN3) and labeled for 15minwith
the Near-IR live/dead indicator NIRViD (Invitrogen Life Technologies,
Paisley, United Kingdom) and mouse anti-bovine CD335, also known as
NKp46 (AKS1; AbD Serotec, Oxfordshire, United Kingdom). Cells were
washed in flow cytometry buffer, and secondary labeling of anti-CD335
was performed using a 1:400 dilution of rat anti-mouse IgG2a conjugated
to allophycocyanin for a further 15 min. After a subsequent wash, cells
were further labeled with combinations of R-phycoerythrin (R-PE)-Ze-
non-labeled (Invitrogen Life Technologies, Paisley, United Kingdom)
mouse anti-bovine CD3 (MM1A; WSU Monoclonal Antibody Centre,
Pullman, Washington, USA), mouse anti-bovine CD4 conjugated to Al-
exa Fluor 647 (CC30; AbD Serotec, Oxfordshire, United Kingdom),
mouse anti-bovine CD8 conjugated to Alexa Fluor 647 (CC63; AbD Se-
rotec, Oxfordshire, United Kingdom), and Alexa Fluor 488-Zenon-la-
beled (Invitrogen Life Technologies, Paisley, United Kingdom) mouse
anti-bovine -TCR1 (GB21a; WSUMonoclonal Antibody Centre, Pull-
man,Washington,USA). Finally, labeled cells werewashed in flow cytom-
etry buffer and resuspended in 150 l of 2% paraformaldehyde (Cytofix;
BD Biosciences, Oxfordshire, United Kingdom) for at least 30 min at 4°C
before analysis on a CyAn ADP analyzer. For capture and analysis, initial
gating was on single, NIRViDlo (live) cells into a subsequent lymphocyte
gate before gating on CellTrace violetlo cells.
Data and statistical analysis. All data representation and statistical
analysis were performed usingGraphPad Prism, version 5.04, andGraph-
Pad InStat, version 3.06 (GraphPad Software, La Jolla, CA, USA). Statis-
tical analysis of IFN- and lymphocyte proliferation data was performed
using a nonparametric repeated-measures analysis of variance (ANOVA;
Friedman test) with a Dunn’s multiple comparisons posttest.
RESULTS
Highly purified PIM molecules can be isolated from virulent
mycobacteria. PIMmolecules differing in the number of acyl and
mannose residues were highly purified from M. tuberculosis. Five
distinct PIM molecules were isolated: PIM2, AcPIM2, Ac2PIM2,
AcPIM6, and Ac2PIM6. In total, these lipids constituted 3% of the
bacterial dry mass after silica gel 60 separation. The ability of the
purificationmethod to isolate highly pure PIMs is shown in Fig. 1,
in which the structures and purity of the different PIMmolecules
were confirmed by ESI-MS. In addition, bands corresponding to
AcPIM2 molecules (that differed only in the number of carbon
atoms in the acyl chains) were clearly resolved by thin-layer chro-
matography (TLC) analysis (see Fig. S1 in the supplemental ma-
terial).
Purified PIMmolecules activate lymphocytes fromM. bovis-
infected cattle. In order to assess the ability of purified PIMs to
induce in vitro immune responses in cattle, PBMC from 10 natu-
rally M. bovis-infected cattle were cultured for 5 days in the pres-
ence of each PIM molecule, and the level of IFN- was measured
by ELISA (Fig. 2A). Both the frequency and strength of IFN-
responses differed depending on the nature of the PIMmolecule.
AcPIM2 was least recognized, inducing responses in only 2 of the
10 animals. PIM2, Ac2PIM2, and Ac2PIM6 were more frequently
recognized, with responses detected in 3 (PIM2) and 4 (Ac2PIM2
and Ac2PIM6) out of 10 animals. AcPIM6 was most frequently
recognized, inducing responses in half of the animals studied. Fur-
thermore, AcPIM6 was the only PIM molecule to induce signifi-
cantly greater levels (P 	 0.01) of IFN- overall than nonstimu-
lated controls.
In addition to measuring IFN- production, we also investi-
gated the ability of the PIM molecules to induce PBMC prolifer-
ative responses in the same animals. Again, the frequency of re-
sponding animals differed depending upon the nature of the PIM
molecule (Fig. 2B). PIM2 failed to induce a proliferative response
in any of the animals studied, while AcPIM2 induced responses in
only 3 out of 10 animals. In contrast, Ac2PIM2, AcPIM6, and
Ac2PIM6 were more frequently recognized, inducing proliferative
responses in 6 (Ac2PIM2 and AcPIM6) and 7 (Ac2PIM6) out of 10
animals. Overall, significantly greater PBMCproliferationwas de-
Pirson et al.
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tected in the Ac2PIM2, AcPIM6, and Ac2PIM6 treatment groups
than in nonstimulated controls, with median values tending to be
greater following AcPIM6 stimulation.
Phenotyping of AcPIM6-responsive proliferating cells by
flow cytometry. As AcPIM6 was the only PIMmolecule to gener-
ate significantly increased levels of IFN- (Fig. 2A) and produced
the greatest increase in the median proliferative response (Fig.
2B), we used this antigen to stimulate PBMC from an M. bovis-
infected animal to characterize the proliferating cell populations
by flow cytometry. Purified protein derivative from M. bovis
(PPD-B) was used as a control antigen. CellTrace violet-labeled
cells were incubated for 5 dayswith antigen before being harvested
and labeled for flow cytometric analysis. After stimulation with
either PPD-B or AcPIM6, three populations of proliferating cells
were identified based on cell surface phenotyping: (i) CD4
T cells
(CD3
 CD4
), (ii) CD8
 T cells (CD3
 CD8
), and (iii) NKT-
like cells (CD3
 CD335
). An example of the gating strategy for
identifying proliferatingNKT cells is highlighted in Fig. 3A, which
demonstrates a greater level of proliferating cells in response to
stimulationwith AcPIM6 (58.29%) than in the non-antigen-stim-
ulated control (29.87%).
The effects of stimulation with either PPD-B or AcPIM6 on the
three different cell populations are summarized in Fig. 3B. Stim-
ulation with PPD-B drove antigen-specific proliferation of ap-
proximately 60%of the CD4
T cells (CD3
CD4
). Similarly, an
antigen-specific proliferative response was seen in approximately
15% of the CD8
 T cells (CD3
 CD8
) to PPD-B. A slight in-
crease in NKT cell (CD3
 CD335
) proliferative responses (ap-
proximately 20%) was also seen to these antigens (Fig. 3B).
StimulationwithAcPIM6 induced only limited proliferation of
CD4
T cells (approximately 5%) and no proliferation of CD8
T
cells above the background (Fig. 3B). In contrast, approximately
30% of the NKT cell populationmounted a proliferative response
after stimulation with AcPIM6 (Fig. 3B). Little or no proliferation
above the unstimulated negative control was seen in the CD3
CD335
 cells or in the CD3
 -TCR
 populations (data not
shown).
DISCUSSION
Mycobacterial lipids have long been implicated in the induction of
responses in both the innate and adaptive cell-mediated immune
responses (17–21). Although one strategy has been published
which allows the isolation of PIMs from the avirulent M. bovis
BCG strain (18, 22–24) and M. tuberculosis H37Rv (22) and cer-
tain synthetic molecules (17, 19, 21), in this study we successfully
developed a novel method for extracting and subsequently highly
purifying and characterizing individual PIM species from the po-
lar fraction of virulentM. tuberculosisH37Rv. The method devel-
oped here improves upon the previously published protocols pri-
marily by using a French press to disrupt the bacterial cells,
thereby increasing PIM yield. Other refinements include the re-
moval of the hot acetone incubation and the use of different re-
verse-phase conditions for PIMpurification. Our strategy allowed
us to isolate a greater yield of more highly purified PIMs, as con-
firmed by ESI-MS, that could be subsequently assayed for their
ability to generate responses in lymphocytes.
To assess the ability of these highly purified PIMs to drive im-
mune responses, the individual molecules were used to stimulate
peripheral lymphocytes isolated from M. bovis-infected cattle.
Only AcPIM6 drove significant levels of IFN- from PBMC (Fig.
2A). Interestingly, whenwhole blood taken from the same animals
was stimulated overnight with the PIM molecules as previously
described (25-27), no IFN- could be measured, and this was not
due to a lack of viability as stimulation with pokeweed mitogen
(PWM) generated high levels of IFN- (data not shown). Al-
though no IFN- production was seen from the whole-blood as-
say, AcPIM6 was able to drive significant production of IFN-
from PBMC incubated for 5 days (Fig. 2A).
There are very few studies showing the effect of mycobacterial
lipids in short-incubation, whole-blood assays. Cell-mediated im-
mune responses to lipid antigens are more commonly assessed by
enzyme-linked immunosorbent spot (ELISpot) assay, with incu-
bation times of at least 48 h required before measurable responses
become apparent (24, 28). Further, the requirement for antigen
processing and presentation of specific PIMs has been demon-
strated previously (20); perhaps the most likely explanation for
the discrepancy between whole-blood and PBMC IFN- re-
sponses is that the frequencies of lipid-responsive cells are low and
that an extended incubation allows for expansion of these cells.
This is supported by our demonstration of strong proliferative
responses induced after stimulation of PBMCwith PIMs (Fig. 2B).
FIG 2 (A) PIM-driven IFN- production as measured by Bovigam ELISA. PBMC were incubated with PIMs at 20 g ml1 for 5 days. Points represent mean
responses from triplicate wells for each of the 10 animals tested; lines represent the samplemedian. ***, P	 0.001. (B) PIM-driven proliferation of bovine PBMC
as measured by [3H]Thy incorporation. Bovine PBMC were stimulated for 5 days with individual PIMs at 20 g ml1. Points represent mean responses from
triplicate wells for each of the 10 animals tested; lines represent the sample median. *, P	 0.05; **, P	 0.01. Nil, nonstimulated controls.
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A recent study has shown that bovineNKT cells are present only at
low frequencies (0.1% to 1.7%) (29).
Previous work usingmice has shown that the ability of PIMs to
generate cell-mediated responses is dependent on the acyl struc-
tures of the molecules. Early work performed using PIM2 and
PIM6 demonstrated that the acyl chain was essential for NKT cell
recruitment while the complexity of themannose residues did not
alter the response (23); however, it was subsequently shown that
the second acyl chain of PIM4 enhances binding to murine CD1d
but that the polar mannose head was essential for antigen recog-
nition, proliferation, and IFN- production (28). As well as the
number and location of acyl chains, their degree of unsaturation
FIG 3 Assessment of proliferating cell phenotype by flow cytometry. (A) Flow cytometric gating strategy. Single, live CD3
CD335
 lymphocytes were assessed
for CellTrace violet labeling, and cells expressing low levels of CellTrace violet were gated for phenotyping. Numbers represent the percentages of proliferating
cells in response to each antigen. FS Lin, forward scatter (linear). (B) Proliferation of CD3
 CD4
, CD3
 CD8
, or CD3
 CD335
 cells in response to either
PPD-B or AcPIM6. Each bar represents the percentage of cells proliferating after subtraction of the unstimulated control.
Pirson et al.
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and cis, but not trans, stereochemistry are critical in determining
antigenicity (14, 30).
The larger and more complex PIM molecules tested here
(Ac2PIM2, Ac2PIM6, and AcPIM6) drove significant levels of pro-
liferation. AcPIM2 also drove proliferation in 3 animals while
PIM2 generated no positive responses.
As AcPIM6 was the only molecule to drive significant IFN-
responses in our study (Fig. 2A) and one of the most potent in-
ducers of proliferation (Fig. 2B), we decided to use AcPIM6 to
characterize the proliferative response. Stimulation with AcPIM6
induced higher levels of proliferation in NKT cells than in CD4

or CD8
 T cells (Fig. 3). However, from these data it is not possi-
ble to tell if the proliferative CD4
 or CD8
 cells also coexpress
CD335 as our flow cytometric labeling panels do not allow the
discrimination; however, this is a distinct possibility.
Although well characterized in humans andmice, the presence
of NKT cells in cattle has been a controversial issue (31–34). Nev-
ertheless, studies have shown that the bovine CD1D gene is ex-
pressed and translated in vivo (35), and recent work has identified
a subset of cattle lymphocytes that express both T cell (CD3) and
NK cell (NKp46) markers, suggesting the presence of an NKT cell
population in bovine peripheral blood (29). Furthermore, bovine
NKT cells have been shown to express both - and -TCRs, to
have a broad TCR repertoire, and to have fully functional NKp46,
CD16, and CD3 signaling pathways (29). Interestingly, these cells
require ligation of their CD3 molecules to produce IFN-. While
this may initially suggest that a CD3 binding component may be
present in our PIM preparations, it is worth noting that we have
not identified the cytokine-producing cells.
The identification of AcPIM6 as a potent immunostimulatory
molecule is of great interest both as a potential vaccine candidate
(21), an adjuvant formulation (36), or a target for attenuation in
the development of novel live vaccines (37). PIMs have also been
used previously as diagnostic reagents for both tuberculosis and
leprosy, although with limited success (38).
In conclusion, we present here the ability to extract and selec-
tively purify PIMs to a high level of purity. These molecules could
be used to stimulate significant IFN- production and drive sig-
nificant proliferation in PBMC fromcattle.Wehave also been able
to identify the proliferative population and, for the first time, we
have shown antigen-specific NKT activation in cattle.
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